Is NIFTP malignant?
Since NIFTP is not ‘malignant’, tumor staging is not necessary and patients are not submitted to thyroid cancer protocols or guidelines.
Is NIFTP benign or malignant?
Despite deleting the word ‘carcinoma’ from its name, NIFTP is not a benign tumor either and is best regarded as a neoplasm with ‘very low malignant potential’. The main goal of the introduction of NIFTP category is to prevent overdiagnosis and overtreatment.
Can NIFTP come back?
These previous researchers found that NIFTP was benign in a cohort of 109 patients, with no recurrence. Notably, subsequent studies have found that the recurrence rate of NIFTP was higher than zero and advised against de-escalation of treatment and loss of follow-up.
What is minimally invasive follicular carcinoma?
We believe that a FCMI is defined as an encapsulated follicular tumor (not papillary), with only small to medium vessel invasion within or immediately adjacent to the tumor capsule and/or up to full-thickness capsular transgression without accompanying extension into the thyroid parenchyma with intervening fibrosis.
Can NIFTP be multifocal?
The multifocal form of NIFTP is present in 2.7–14.7% of patients (10, 40, 42). The coexistence of a malignant lesion in the same or in the second lobe of the thyroid may affect 14.9–46.3% of NIFTP patients (it most often coexists with papillary thyroid microcarcinoma) (10, 21, 41).
What does NIFTP stand for?
Non-invasive follicular thyroid neoplasm with papillarylike nuclear features (NIFTP) is a new name for a very low risk thyroid tumor previously known as an Encapsulated Non-invasive Follicular Variant Papillary Thyroid Carcinoma.
How common is NIFTP?
The incidence of NIFTP tumors has been reported to be between 16-23% and, when properly diagnosed using strict pathologic criteria, is felt to have a very favorable prognosis.
What is Nifpt?
What causes follicular carcinoma?
It’s not clear what causes thyroid cancer. Thyroid cancer occurs when cells in your thyroid undergo genetic changes (mutations). The mutations allow the cells to grow and multiply rapidly. The cells also lose the ability to die, as normal cells would.
How can you tell the difference between follicular adenoma and carcinoma?
The only difference between a follicular adenoma and a follicular carcinoma is that all of the abnormal cells in a follicular adenoma are separated from the normal thyroid gland by a thin tissue barrier called a tumour capsule.
How common is Niftp?
What is NIFTP?
WHAT IS NIFTP? Non-invasive follicular thyroid neoplasm with papillarylike nuclear features (NIFTP) is a new name for a very low risk thyroid tumor previously known as an Encapsulated Non-invasive Follicular Variant Papillary Thyroid Carcinoma.
What is the prognosis of niftps?
Although the cells in a NIFTP have features that look like papillary thyroid cancer, this finding alone does not mean NIFTPs are malignant. Because NIFTP tumors are not invasive and are contained within the tumor capsule, they are considered to have an extremely low risk of adverse outcomes like tumor recurrence or spread (metastasis).
Is NIFTP A malignant thyroid tumor?
Since NIFTP is not ‘malignant’, tumor staging is not necessary and patients are not submitted to thyroid cancer protocols or guidelines. We believe that patients with NIFTP without associated malignancy and without nodules detected by US of the remnant lobe (if submitted to lobectomy) can be managed like those with follicular adenoma.
Should noninvasive tumors with <1% papillae be included in NIFTP-efvptc spectrum?
In fact, a recent study advocates for an even stricter approach noting that even with noninvasive tumors with <1% papillae, a small subset may show nodal metastases, and BRAF V600E mutations, the latter which should not be seen in NIFTP-EFVPTC spectrum of tumors (see below).